This Week in Cardiology
Oct 16, 2026 This Week in Cardiology Podcast
Sponsors in this episode
No sponsor reads found in this episode's notes.
Host-read ads that the notes don't mention can't be found this way.
Show notes
Some promising studies in amyloidosis, aficamten in nonobstructive HCM, costs of the microaxial flow pump in cardiogenic shock, and more on the VESALIUS trial of evolocumab are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Light Chain Amyloidosis – A Potentially Helpful Drug
Anselamimab Does Not Reduce Light-Chain Amyloidosis Deaths
https://www.medscape.com/viewarticle/anselamimab-does-not-reduce-light-chain-amyloidosis-deaths-2026a1000z79
II Aficamten in Nonobstructive HCM: The ACACIA trial
III Microaxial Flow Pump Cost Analysis of Danger Shock
IV More on Evolocumab at ESC: Vesalius Trial Substudies
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
https://www.medscape.com/viewarticle/1003092
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
From the show's RSS feed.